aminoimidazole carboxamide has been researched along with Atherogenesis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brüne, B; Kemmerer, M; Namgaladze, D; von Knethen, A | 1 |
| Chen, B; Li, J; Zhu, H | 1 |
| Ma, A; Wang, J; Zhao, M; Zhu, H | 1 |
| Belcher, JD; Geng, JG; Huo, Y; Slungaard, A; Tang, R; Viollet, B; Wang, H; Wang, J; Wu, C; Zhang, C; Zhang, W; Zhu, C | 1 |
| Feng, X; Li, D; Ling, W; Wang, D; Wang, Y; Xia, M | 1 |
| Chen, Z; Jia, F; Lu, G; Wu, C | 1 |
6 other study(ies) available for aminoimidazole carboxamide and Atherogenesis
| Article | Year |
|---|---|
AICAR inhibits PPARγ during monocyte differentiation to attenuate inflammatory responses to atherogenic lipids.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Anti-Inflammatory Agents; Atherosclerosis; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Enzyme Activation; Enzyme Activators; Gene Expression Regulation; Humans; Inflammation; Interleukin-4; JNK Mitogen-Activated Protein Kinases; Lipoproteins, LDL; Macrophages; Monocytes; Palmitic Acid; Phenotype; PPAR gamma; Ribonucleotides; RNA Interference; RNA, Messenger; Transfection | 2013 |
AMP-activated protein kinase attenuates oxLDL uptake in macrophages through PP2A/NF-κB/LOX-1 pathway.
Topics: Adenosine; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Foam Cells; Lipoproteins, LDL; Macrophages; Mice; Mice, Knockout; NF-kappa B; Okadaic Acid; Protein Phosphatase 2; Ribonucleotides; Scavenger Receptors, Class E | 2016 |
AMPK activation reduces the number of atheromata macrophages in ApoE deficient mice.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Antigens, Ly; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Biphenyl Compounds; Cell Line; Cell Migration Inhibition; Chemotaxis; Disease Models, Animal; Enzyme Activation; Enzyme Activators; Genetic Predisposition to Disease; Humans; Macrophages; Metformin; Mice, Knockout; Phenotype; Pyrones; Receptors, CCR2; Ribonucleotides; Signal Transduction; Thiophenes | 2017 |
Acadesine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/Akt signaling pathway.
Topics: Adenosine A2 Receptor Antagonists; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Atherosclerosis; Blood Coagulation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Activation; Fibrinolytic Agents; Humans; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; NF-kappa B; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Receptor, Adenosine A2A; Ribonucleosides; RNA, Messenger; Sepsis; Signal Transduction; Thromboplastin; Transcription Factor AP-1; Triazines; Triazoles; Up-Regulation; Venous Thrombosis | 2010 |
Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice.
Topics: 3' Untranslated Regions; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; CD36 Antigens; Cell Line; Cholesterol; Foam Cells; Gene Expression Regulation, Enzymologic; Humans; Hypoglycemic Agents; Lipoproteins; Macrophages, Peritoneal; Mice; Mice, Knockout; Ribonucleotides | 2010 |
Atorvastatin inhibits homocysteine-induced endoplasmic reticulum stress through activation of AMP-activated protein kinase.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blotting, Western; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Heptanoic Acids; Homocysteine; Human Umbilical Vein Endothelial Cells; Humans; Lipids; Mice; Polymerase Chain Reaction; Pyrroles; Ribonucleotides; Time Factors | 2012 |